The National Medical Products Administration (NMPA) has cleared Yochanra (tinengotinib) for adult patients with unresectable ...

Koray Kavukcuoglu, DeepMind's chief technology officer and Google's chief AI architect, is taking on the operational ...

At its third attempt, Replimune has finally won FDA approval for its advanced melanoma treatment RP1, giving the company its ...

Tarsus is paying $450 million upfront for Alkeus – made up of $270 million in cash and $180 million in stock – with another ...

Takeda's orexin agonist Orzeyful has been approved in the US to treat narcolepsy type 1 (NT1) in adults, becoming the first ...

For an emerging biopharma company developing an innovative therapy for a rare condition, 2026 presents a dilemma that may ...

Moderna has started first-in-human testing of its mRNA vaccine against Bundibugyo Ebola virus (BDBV), now causing the ...

There's a change at the helm of Johnson & Johnson's pharma division in the offing, as executive vice president Jennifer ...

The CDC has permanent leadership in place for the first time since August 2025, after the US Senate confirmed the appointment ...

Sentiment towards Novo Nordisk was also hit by the acknowledgement that it has decided to abandon the development of ...

For decades, direct-to-consumer (DTC) advertising has been a defining feature of the US healthcare system. Across the nation, ...

Patients in England with ultra-rare kidney disease nephropathic cystinosis will soon be able to access a therapy that has ...